ACCU-TELL® SARS-CoV-2 Neutralizing Antibody Cassette

Globally, as of 16 June 2021, there have been over 176 million confirmed cases of COVID-19, including over 3.8 million deaths, reported to WHO. As of 14 June 2021, a total of over 2.3 billion vaccine doses have been administered.

Vaccines contain weakened or inactive parts of a particular organism (antigen) or the blueprint for producing antigens rather than the antigen itself, that triggers an immune response within the body, that is, the production of long-lived antibodies and development of memory cells. In this way, the body is trained to fight the specific disease-causing organism, building up memory of the pathogen so as to rapidly fight it if and when exposed in the future.

ACCU-TELL® SARS-CoV-2 Neutralizing Antibody Cassette (Whole Blood/Serum/Plasma) is a rapid chromatographic immunoassay for the qualitative detection of neutralizing antibodies to SARS-CoV-2 in human whole blood, serum, or plasma as an aid in the diagnosis of the presence of neutralizing antibodies to SARS-CoV-2. The subpopulation of the binding antibodies that can block cellular infiltration and replication of the virus are named neutralizing antibodies.

Our SARS-CoV-2 Neutralizing Antibody Cassette (Whole Blood/Serum/Plasma) was compared with MNA50 assay (Microneutralization Assay) at 1:10 dilution to evaluate the efficacy and the study data showed the absolutely high accuracy.